These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 2850903

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Effects of an enzymatically depolymerized heparin as compared with conventional heparin in healthy volunteers.
    Mätzsch T, Bergqvist D, Hedner U, Ostergaard P.
    Thromb Haemost; 1987 Feb 03; 57(1):97-101. PubMed ID: 3590085
    [Abstract] [Full Text] [Related]

  • 23. Low molecular weight heparins: antithrombotic and haemorrhagic effects and standardization.
    Barrowcliffe TW, Thomas DP.
    Acta Chir Scand Suppl; 1988 Feb 03; 543():57-64. PubMed ID: 2847459
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. The effect of subcutaneous injection of unfractionated and low molecular weight heparin on thrombin generation in platelet rich plasma--a study in human volunteers.
    Bendetowicz AV, Kai H, Knebel R, Caplain H, Hemker HC, Lindhout T, Béguin S.
    Thromb Haemost; 1994 Nov 03; 72(5):705-12. PubMed ID: 7900078
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. How useful is the monitoring of (low molecular weight) heparin therapy by anti-Xa assay? A laboratory perspective.
    Favaloro EJ, Bonar R, Aboud M, Low J, Sioufi J, Wheeler M, Lloyd J, Street A, Marsden K, RCPA QAP in Haematology.
    Lab Hematol; 2005 Nov 03; 11(3):157-62. PubMed ID: 16174600
    [Abstract] [Full Text] [Related]

  • 31. Evaluation of hemostatic and fibrinolytic alterations associated with daily administration of low-molecular-weight heparin for a 12-week period.
    Lojewski B, Bacher P, Iqbal O, Walenga JM, Hoppensteadt D, Leya F, Fareed J.
    Semin Thromb Hemost; 1995 Nov 03; 21(2):228-39. PubMed ID: 7660145
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Comparative human pharmacology of low molecular weight heparins.
    Harenberg J, Stehle G, Augustin J, Zimmermann R.
    Semin Thromb Hemost; 1989 Oct 03; 15(4):414-23. PubMed ID: 2554502
    [Abstract] [Full Text] [Related]

  • 34. Comparison of a low-molecular-weight heparin (nadroparin calcium) and unfractionated heparin as adjunct to coronary thrombolysis with alteplase and aspirin in dogs.
    Jun L, Arnout J, Vanhove P, Dol F, Lormeau JC, Herbert JM, Collen D, Van de Werf F.
    Coron Artery Dis; 1995 Mar 03; 6(3):257-63. PubMed ID: 7788040
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model.
    Biemond BJ, Levi M, Nurmohamed MT, Büller HR, ten Cate JW.
    Thromb Haemost; 1994 Sep 03; 72(3):377-80. PubMed ID: 7855787
    [Abstract] [Full Text] [Related]

  • 38. The effect of calcium chloride on anti-Xa activity of heparin and its molecular weight fractions.
    Barrowcliffe TW, Le Shirley Y.
    Thromb Haemost; 1989 Nov 24; 62(3):950-4. PubMed ID: 2556814
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.